Skip to main content
← All articles
nitrous oxideharm reductionB12nerve damagewhippets

Nitrous Oxide and Nerve Damage: The B12 Risk Nobody Talks About

Whippets (nitrous oxide) can permanently damage your spinal cord and nerves by depleting vitamin B12. The mechanism, who's at risk, and early symptoms.

May 27, 2026 · Jordan Mercer

Not medical advice. This article is for harm reduction and educational purposes only. Nothing here is a recommendation to use any substance. If you are experiencing a medical emergency, call your local emergency services immediately. Some links may be affiliate links — we earn a small commission at no cost to you.

Nitrous oxide (laughing gas, whippets, nangs) permanently inactivates vitamin B12 in your body every time you use it. For most people who use occasionally, this matters very little. For people who use heavily or repeatedly — or who already have low B12 — it can destroy the insulation on your spinal cord and peripheral nerves, causing a condition called subacute combined degeneration (SCD) that can leave you with permanent weakness, loss of balance, and numbness. The neurological damage from heavy nitrous use is not theoretical. It is documented in hundreds of patients, confirmed on MRI, and in severe cases it does not reverse.

Quick answers

Can nitrous oxide actually damage your nerves? Yes. Heavy or repeated use causes B12 depletion severe enough to damage myelin — the protective sheath around nerves — especially in the spinal cord. Hundreds of cases have been documented in medical literature since the early 2000s.

Who is most at risk? People with pre-existing low or low-normal B12: vegans, vegetarians, people taking metformin or proton pump inhibitors (PPIs), and older adults. But cases have also occurred in people with normal baseline B12 who used very heavily over weeks or months.

What does nitrous-related nerve damage feel like? Tingling or numbness in the hands and feet (glove-and-stocking distribution), difficulty walking or maintaining balance, electric-shock sensations down the spine when bending your neck (called Lhermitte’s sign), and in advanced cases, leg weakness and spasticity.

Is it reversible? If caught early and treated with the right form of B12 (injectable hydroxocobalamin), most patients improve significantly. Treatment delayed by weeks to months correlates with incomplete recovery. Some patients are left with permanent deficits.

Does taking B12 supplements before use prevent damage? Possibly, but this is community consensus, not RCT-proven. Importantly, standard cyanocobalamin supplements may be less effective than hydroxocobalamin for this specific situation. And supplements do not eliminate the risk — they may only buffer it.


What’s actually happening: the mechanism

Nitrous oxide works in the brain by blocking NMDA receptors, which produces the dissociative, euphoric effect. But at the same time, it irreversibly oxidizes the cobalt atom at the center of vitamin B12 (cobalamin), converting it from its active Co(I) form to inactive Co(III).

This matters because active B12 is required for a single critical enzyme: methionine synthase. Methionine synthase converts homocysteine to methionine and recycles folate so it can be used. When methionine synthase goes offline, two things happen:

  1. Myelin synthesis breaks down. Methionine is the precursor for SAM (S-adenosylmethionine), the universal methyl donor your body uses for myelin maintenance. Without it, the fatty insulation on nerve fibers starts to degrade.
  2. Homocysteine accumulates. Elevated homocysteine is directly neurotoxic.

A single recreational use inactivates some B12, but your body’s stores are normally sufficient to compensate. The problem emerges with repeated, heavy use — or when someone starts with depleted stores. There is no antidote to the oxidation: the affected B12 molecules are permanently inactivated and must be replaced.

This mechanism is fully established biochemically and confirmed in human clinical data.


What the research actually shows

The neurological harm from recreational nitrous use has been documented in hundreds of published cases, with a sharp increase in frequency tracked across neurology services in the UK, the Netherlands, and Australia since the early 2010s.

Van Amerongen et al. 2020 (British Journal of Anaesthesia) conducted a systematic review covering 137 published cases of nitrous-oxide-induced myeloneuropathy. Mean patient age was 25. Vegans and vegetarians were significantly overrepresented relative to the general population. Nearly all patients had used more than occasionally — most described sessions involving dozens to hundreds of cartridges (8g each) over weeks or months.

Lan et al. 2019 (Brain & Development, PMID 30611595) reported a case series of 9 adolescent SCD cases from recreational N₂O use. 6 of 9 (67%) had low or low-normal B12 at presentation. 8 of 9 showed spinal cord demyelination on MRI. All recovered full muscle strength with B12 treatment, though five retained persistent sensory deficits.

Thompson et al. 2015 (Practical Neurology, PMID 25977272) described three cases of peripheral neuropathy linked to recreational N₂O use, noting that not all patients present with the classic spinal cord pattern and that functional B12 deficiency can occur even without frankly low serum levels.

It is important to note that all neurological harm data is from case reports and case series (Tier 8 evidence in an evidence hierarchy). No RCTs exist, for obvious ethical reasons. However, the biochemical mechanism is unambiguous, the temporal relationship between use and symptoms is well-documented, and the condition reverses (to varying degrees) with B12 treatment — making causality effectively certain even without a controlled trial.


Subacute combined degeneration: what it looks like clinically

SCD is called “combined” because it typically affects multiple nerve pathways simultaneously. The classic presentation develops over days to weeks after heavy exposure:

Peripheral neuropathy (early)

  • Tingling, numbness, or burning in the hands and feet
  • Often symmetrical, starting at the fingertips and toes
  • This is the earliest warning sign and the most commonly reported

Posterior column involvement (progresses from early symptoms)

  • Loss of vibration sense and proprioception (sense of joint position)
  • Unsteady gait, especially in the dark when visual compensation isn’t available
  • Difficulty with fine motor tasks

Lhermitte’s sign

  • An electric-shock or buzzing sensation that shoots down the spine and into the limbs when the neck is bent forward
  • Classic sign of cervical spinal cord involvement; not unique to nitrous but very commonly reported in these cases

Lateral corticospinal tract involvement (advanced)

  • Leg weakness, spasticity, brisk reflexes
  • Difficulty walking or climbing stairs
  • In severe cases, paralysis

On MRI, these cases show characteristic T2 hyperintensity (bright signal) in the posterior and lateral columns of the spinal cord — the visual signature of demyelination.


Who is highest risk

Pre-existing low B12 is the single most important risk factor. The following groups are significantly more likely to have low or borderline B12 before they ever use nitrous:

  • Vegans and vegetarians (B12 comes almost exclusively from animal products; dietary sources alone often can’t maintain adequate stores)
  • People taking metformin (reduces B12 absorption; commonly used for diabetes and PCOS)
  • People taking proton pump inhibitors (omeprazole, lansoprazole, etc.) long-term
  • People with Crohn’s disease, celiac disease, or gastric bypass
  • Older adults (absorption decreases with age)

Heavy or frequent use is the second major factor. Documented cases have occurred across a spectrum of use patterns, but the clearest cases involve large-volume sessions (100+ cartridges at a time) or repeated use over weeks and months. Single or occasional moderate use has not been documented to cause clinical SCD in people with normal baseline B12.

The compounding problem: Serum B12 levels can appear normal in early depletion. Active B12 (holotranscobalamin) and methylmalonic acid are more sensitive functional markers but are not routinely checked. You can feel fine and test borderline-normal while your functional B12 reserve is critically low.


Treatment: what to do if you have symptoms

If you develop tingling in your extremities, balance problems, or Lhermitte’s sign — especially after heavy nitrous use — these are urgent neurological symptoms. Get evaluated promptly.

Treatment is injectable hydroxocobalamin, not oral cyanocobalamin (the common over-the-counter form). Hydroxocobalamin is a better substrate for the body’s B12 pathway and is the standard of care for this condition. Oral B12 supplementation alone is typically insufficient for established neurological damage.

Time matters. Recovery in the literature is closely tied to how quickly treatment begins. Patients treated within days to weeks of symptom onset typically recover well. Patients with months of progressive symptoms before treatment have more variable and often incomplete outcomes. If you’re experiencing symptoms, do not wait to see if they improve on their own.

Tell your doctor about your nitrous use — they cannot order the right tests or start the right treatment without accurate information about what caused the symptoms.


The honest harm reduction position

Occasional recreational nitrous use is a very different risk profile from heavy repeated use. The published cases of neurological damage almost universally involve frequent, large-volume use, pre-existing B12 deficiency, or both. Someone using a few cartridges at a festival and otherwise maintaining good B12 status is in a fundamentally different category from someone using hundreds of cartridges a week.

That said, there is no established safe threshold. What is known: frequency of use and baseline B12 status are the two levers that most reliably predict risk. If you use nitrous regularly, it is worth actually checking your B12 level — not just assuming it’s fine.

For a full breakdown of nitrous oxide effects, risks, and interactions, see our nitrous oxide harm reduction guide.


Sources: PMID 30611595 | PMID 25977272 | van Amerongen et al. 2020, Br J Anaesth (DOI 10.1016/j.bja.2019.11.027)